Lucid Capital analyst Elemer Piros initiated coverage of Ocugen (OCGN) with a Buy rating and $15 price target Ocugen is developing next-generation, genetic medicines with the intention to save vision in genetic disorders of the eye, the analyst tells investors in a research note. The firm believes OCU400 in retinitis pigmentosa could see peak sales of $3.2B by 2032.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen Faces Merger Termination with Carisma Therapeutics
- Ocugen’s Strategic Advancements and Promising Prospects Justify Buy Rating
- Ocugen Signs Exclusive License Agreement with Kwangdong
- Tesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz
- Ocugen executes licensing agreement with Kwangdong Pharmaceutical